Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the ona domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/risezcom/public_html/cord-blood.org.uk/wp-includes/functions.php on line 6170
New Trial Tests Cord Blood Transplants to Cure Leukemia and HIV - Cord Blood

Cord Blood

and Stem Cell Banking

New Trial Tests Cord Blood Transplants to Cure Leukemia and HIV

Pipettes being used in a laboratory

In a groundbreaking study, researchers are testing cord blood transplants as a potential cure for both leukemia and HIV. This research builds on the success of previous patients who have undergone similar transplants and achieved remarkable results. While the procedure is currently only available to those with life-threatening cancer, the ultimate goal is to develop a single injection that can modify a patient’s own cells to make them resistant to HIV, even in low-income countries.

The Study

Dr. Hans-Peter Kiem, a transplant physician at Fred Hutch, is part of the research team dedicated to finding an HIV cure. He has collaborated with other experts to develop the cord blood trial. The study aims to replicate the success of previous patients in controlling and potentially eliminating HIV with protected immune cells. However, it is essential to note that these transplants come with significant risks and are challenging for patients to endure.

The Potential Solution

Despite the risks associated with cord blood transplants, the research has shed light on a potential solution. By engineering T cells, which are vital components of the immune system, with HIV-blocking traits, researchers hope to develop a single injection that can make a patient’s cells resistant to HIV. This breakthrough could be especially beneficial for patients in low- or middle-income countries.

The Challenges

Launching the cord blood trial has faced numerous obstacles, including freezing difficulties and delays due to the impact of COVID-19 on clinical studies. However, these setbacks have not deterred the researchers from pursuing this critical study. A newly authorized clinical trial will use a reformulated version of the cord blood product, which contains cells from multiple donors. These cells fight off infections temporarily and then die, while the transplanted cord blood cells carry their HIV-resistance traits.

The Study Process

Participants in the study will be randomly assigned to receive different doses of radiation and chemotherapy as part of the conditioning process to eradicate leukemia and potentially destroy HIV-infected cells. After the cord blood infusion, patients will continue taking antiviral drugs and undergo close monitoring by their hospitals. Blood samples will be regularly collected to track leukemia and check for HIV reservoirs.

Looking Ahead

Although conditioning regimes may eliminate lingering HIV reservoirs, previous attempts have not successfully replicated the results seen in previous patients. Researchers suspect that the transplanted immune cells resistant to HIV may control the virus by detecting and attacking latent virus-carrying cells, similar to how they target malignant blood cells in leukemia. Sophisticated analyses of patient blood specimens will be conducted to determine if and when patients can stop taking HIV medication and to detect early signs of the virus if it reappears.

Conclusion

The cord blood transplant trial offers new hope in the fight against leukemia and HIV. While the journey to finding a cure is challenging, the research is promising. By leveraging the power of immune cells and developing innovative treatments, researchers aim to offer long-lasting solutions for patients worldwide.